Artesunate-Amodiaquine and Artemether Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
No Thumbnail Available
Date
2016
Journal Title
Journal ISSN
Volume Title
Publisher
PLOS ONE
Abstract
The adoption of Artemisinin based combination therapies (ACT) constitutes a basic strategy
for malaria control in sub-Saharan Africa. Moreover, since cases of ACT resistance have
been reported in South-East Asia, the need to understand P. falciparum resistance mecha nism
to ACT has become a global research goal. The selective pressure of ACT and the
possibility that some specific Pfcrt and Pfmdr1 alleles are associated with treatment failures
was assessed in a clinical trial comparing ASAQ to AL in Nanoro. Dried blood spots col lected
on Day 0 and on the day of recurrent parasitaemia during the 28-day follow-up were
analyzed using the restriction fragments length polymorphism (PCR-RFLP) method to
detect single nucleotide polymorphisms (SNPs) in Pfcrt (codon76) and Pfmdr1 (codons 86,
184, 1034, 1042, and 1246) genes. Multivariate analysis of the relationship between the
presence of Pfcrt and Pfmdr1 alleles and treatment outcome was performed. AL and ASAQ
exerted opposite trends in selecting Pfcrt K76T and Pfmdr1-N86Y alleles, raising the poten tial
beneficial effect of using diverse ACT at the same time as first line treatments to reduce
the selective pressure by each treatment regimen. No clear association between the pres ence
of Pfcrt and Pfmdr1 alleles carried at baseline and treatment failure was observed
Description
This article is published by Plos One and is also available at https://doi.org/10.1371/journal.pone.0151565
Keywords
Citation
Sondo P, Derra K, Diallo Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, et al. (2016) Artesunate-Amodiaquine and Artemether Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso